- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 23 Months
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 260
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Alhambra, California • La Jolla, California • Aurora, Colorado + 3 more
- Conditions
- Influenza, Human, COVID-19, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Interventions
- Not listed
- Lead sponsor
- Evidation Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,157 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- San Mateo, California
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
- Interventions
- The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
- Diagnostic Test
- Lead sponsor
- Thermo Fisher Scientific, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,909 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 17
- States / cities
- San Diego, California • Lake City, Florida • Miami, Florida + 13 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV cps2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- La Jolla, California • Long Beach, California • Denver, Colorado + 1 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 11,194 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 35 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 1030s vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Laurel, Maryland
- Conditions
- Lower Respiratory Tract Illness
- Interventions
- RSVpreF, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 38,861 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 119 more
- Conditions
- RSV Infections
- Interventions
- Not listed
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- Up to 36 Months
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Syracuse, New York • Seattle, Washington
- Conditions
- Respiratory Syncytial Virus
- Interventions
- EDP-938, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Anaheim, California + 9 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 32
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 28 more
- Conditions
- Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
- Interventions
- Placebo, SeVRSV Vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- ABRYSVO
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years to 50 Years
- Enrollment
- 1 participant
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALS-008176, Placebo
- Drug
- Lead sponsor
- Alios Biopharma Inc.
- Industry
- Eligibility
- Up to 12 Months
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more
- Conditions
- Respiratory Syncytial Virus Immunization
- Interventions
- RSV vaccine candidate, Placebo
- Biological · Other
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 865 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 22 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV Vaccine, Non-exposure to RSV Vaccine
- Biological · Other
- Lead sponsor
- CorEvitas
- Network
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 2,062 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
- Interventions
- ALVR106, Placebo
- Biological
- Lead sponsor
- AlloVir
- Industry
- Eligibility
- 17 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- In Vitro Diagnostic device to aid in diagnosis
- Device
- Lead sponsor
- Quidel Corporation
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 2,468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Panorama City, California • Boynton Beach, Florida + 11 more
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- RSVt Vaccine, Control Group
- Biological · Other
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 23 Months
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Norfolk, Nebraska • Omaha, Nebraska
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Lumicitabine, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 28 Days to 36 Months
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Long Beach, California • Kansas City, Missouri • Syracuse, New York + 3 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT 60 µg, RSV MAT 120 µg, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 534 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Arexvy (2 doses total), Arexvy (3 doses total), Arexvy (1 dose total), Placebo
- Biological · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID cp ΔM2-2 Vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more
- Conditions
- Covid19
- Interventions
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray
- Biological
- Lead sponsor
- Meissa Vaccines, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Raleigh, North Carolina